כל המחקרים
פעיל אך לא מגייסשלב 2התערבותי

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

This research study is for people with a type of bladder cancer called urothelial cancer that has spread to other parts of the body (metastatic) or cannot be surgically removed. The main goal is to find out how safe and effective a new drug, sacituzumab govitecan, is. Researchers are testing this drug by itself and in combination with other treatments such as pembrolizumab, avelumab, and domvanalimab. They will also be looking at how well established chemotherapy drugs like cisplatin and carboplatin work with these newer treatments. This study aims to offer new treatment options for patients whose cancer has progressed after previous therapies.

במבט חטוף

סטטוס
פעיל אך לא מגייס
שלב
שלב 2
נותן חסות
גיליאד סיינסז
יעד הרשמה
502
התחל
13 Aug 2018
השלמה משוערת
01 Apr 2030

על מה המחקר הזה?

This study is about finding better ways to treat a specific type of bladder cancer called urothelial cancer. This is when the cancer has either spread to other parts of the body (known as metastatic cancer) or it's grown so much that doctors can't remove it with surgery. The doctors running this study want to see how well a new drug, called sacituzumab govitecan, works, both on its own and when combined with other medicines.

Urothelial cancer can be very challenging to treat, especially when it has spread. Traditional treatments might include chemotherapy, but sometimes these stop working, or patients can't have them. This study is exploring different combinations of drugs, including some that are already used and some newer ones, to see if they can offer better results for patients. The hope is to find treatments that are both effective at controlling the cancer and as safe as possible.

The study is divided into different groups, called 'cohorts,' to test various drug combinations. Some parts of the study are already set up to test specific combinations, while others are randomised, which means patients would be put into a group by chance, much like flipping a coin. However, one of these randomised groups (Cohort 5) has been stopped. The results from this research will help doctors understand if these new approaches can become standard treatments in the future.

נקודות עיקריות

  • The study explores new treatments for advanced urothelial (bladder) cancer.
  • It tests sacituzumab govitecan, alone or with other drugs, to assess safety and effectiveness.
  • Participation involves regular clinic visits, tests, and receiving study medication.
  • היתרונות הפוטנציאליים כוללים גישה לטיפולים חדשים; הסיכונים הפוטנציאליים כוללים תופעות לוואי.
  • Your eligibility depends on your age, general health, and previous cancer treatments.
  • You can withdraw from the study at any time without affecting your future care.

מי עשוי להיות זכאי?

To join this study, people typically need to be at least 18 years old (or 19 in South Korea) and generally well enough to take part. This is often measured by something called an ECOG score of 0 or 1, which means you're able to carry out most daily activities without much difficulty.

You would also need to have healthy kidney and liver function, and your blood counts (like red and white blood cells) should be within a healthy range without needing blood transfusions. Doctors usually expect you to have a life expectancy of at least three months to make sure you can benefit from and complete the study.

Beyond these general requirements, there are specific conditions related to your previous cancer treatment. For example, some parts of the study are for people whose urothelial cancer has returned or worsened after having chemotherapy that included platinum-based drugs (like cisplatin or carboplatin) or after specific immunotherapy treatments. Other parts are for people who couldn't have platinum-based chemotherapy initially or who haven't had it for their advanced cancer.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. Are you 18 years old or older (19 in South Korea)?
  2. Are you generally well and able to carry out most daily activities?
  3. Do you have healthy kidney and liver function?
  4. Has your urothelial cancer spread or cannot be removed by surgery?
  5. Have you previously had treatment for your cancer that may have included platinum-based chemotherapy or immunotherapy?
  6. Are you expected to live for at least three more months?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

If you take part in this study, the doctors and nurses will monitor your health closely. This will involve regular visits to the clinic, where you'll have various tests, such as blood tests, urine tests, and scans, to see how the treatment is working and to check for any side effects. You will receive the study medication (or combination of medications) according to a set schedule, which will be carefully explained to you by the study team.

The exact number and timing of visits will depend on which treatment group you are in and how you respond to the medication, but typically, these studies involve frequent visits initially, becoming less frequent over time. The study will continue for as long as the treatment is beneficial and you are tolerating it well, followed by a period of observation where your health will still be monitored. The total duration of participation varies for each patient, but you would be fully informed of the expected timeline before you start.

סיכונים ותועלות פוטנציאליים

Taking part in a clinical trial might offer potential benefits, such as gaining access to new treatments before they are widely available, which could help manage your cancer. However, there are also potential risks, as the treatments are still being studied. You might experience side effects from the medications, some of which could be serious or unexpected. The study team will carefully explain all known and potential risks to you. It's important to remember that participation is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your future medical care.

Locations (128)

  • The University of Arizona Cancer Center-North Campus
    מיקוד מאומת
    טוסון, ארצות הברית
  • אוניברסיטת קליפורניה בסן פרנסיסקו
    מיקוד מאומת
    סן פרנסיסקו, ארצות הברית
  • מרכזי סרטן הרי הרוקי
    מיקוד מאומת
    Littleton, United States
  • Smilow Cancer Hospital at Yale-New Haven
    מיקוד מאומת
    ניו הייבן, ארצות הברית
  • Mount Sinai Comprehensive Cancer Center
    מיקוד מאומת
    מיאמי ביץ', ארצות הברית
  • Woodlands Medical Specialists, PA
    מיקוד מאומת
    פנסקולה, ארצות הברית
  • מרכז הסרטן מופיט
    מיקוד מאומת
    טמפה, ארצות הברית
  • Winship Cancer Institute, Emory University
    מיקוד מאומת
    אטלנטה, ארצות הברית
  • University of Illinois Cancer Center
    מיקוד מאומת
    שיקגו, ארצות הברית
  • המרכז הרפואי של אוניברסיטת שיקגו
    מיקוד מאומת
    שיקגו, ארצות הברית
  • Southern Illinois University School of Medicine, Simmons Cancer Institute
    מיקוד מאומת
    Springfield, United States
  • Norton Cancer Institute, Downtown
    מיקוד מאומת
    לואיוויל, ארצות הברית

שאלות נפוצות

What is urothelial cancer?

Urothelial cancer is a type of cancer that starts in the cells lining the bladder, ureters (tubes from kidneys to bladder), and urethra (tube from bladder out of body). It's the most common type of bladder cancer.

What does 'metastatic' mean?

'Metastatic' means the cancer has spread from where it started to other parts of the body, such as the bones, lungs, or liver.

What is sacituzumab govitecan?

Sacituzumab govitecan is a type of targeted drug called an antibody-drug conjugate. It's designed to find cancer cells and deliver a chemotherapy-like medicine directly to them, hopefully causing less harm to healthy cells.

What are 'platinum-containing regimens'?

These are chemotherapy treatments that include drugs like cisplatin or carboplatin. They are often used as a standard treatment for many cancers, including urothelial cancer.

האם אני בהחלט אקבל את התרופה החדשה?

It depends on which treatment group you are placed into. Some groups test sacituzumab govitecan on its own or with other new drugs, while others might compare it to standard treatments or different combinations. Your doctor will discuss this with you before you agree to join.

כיצד לגלות עוד

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.